Efungumab Biosimilar – Anti-HSP91 homolog mAb – Research Grade from ProteoGenix; catalogue PX-TA1127; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Efungumab Biosimilar is a monoclonal antibody (mAb) that has been developed as a biosimilar version of the original drug, Efungumab. This antibody specifically targets the heat shock protein 90 (HSP90) homolog, which has been identified as a potential therapeutic target for various diseases. In this article, we will provide a scientific description of Efungumab Biosimilar, including its structure, activity, and potential applications.
Efungumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the target antigen, while the constant region plays a role in effector functions such as complement activation and antibody-dependent cellular cytotoxicity.
Efungumab Biosimilar specifically targets the HSP90 homolog, which is a highly conserved protein that plays a crucial role in cell survival and proliferation. This protein is overexpressed in many types of cancer, making it an attractive therapeutic target. By binding to the HSP90 homolog, Efungumab Biosimilar inhibits its activity, leading to the inhibition of cell growth and survival. This mechanism of action makes it a promising candidate for the treatment of various cancers.
Efungumab Biosimilar has shown promising results in preclinical studies for the treatment of various types of cancer, including breast, lung, and prostate cancer. It has also been evaluated in clinical trials for the treatment of multiple myeloma, a type of blood cancer. In addition to its potential as an anti- cancer therapy, Efungumab Biosimilar has also shown potential in the treatment of autoimmune diseases, as the HSP90 homolog has been implicated in the pathogenesis of these diseases.
As mentioned earlier, Efungumab Biosimilar exerts its therapeutic effects by targeting the HSP90 homolog. This protein is known to play a critical role in the proper folding and stabilization of many cellular proteins, including oncogenic proteins in cancer cells. By binding to the HSP90 homolog, Efungumab Biosimilar disrupts its chaperone function, leading to the degradation of these oncogenic proteins and ultimately inhibiting the growth and survival of cancer cells.
Efungumab Biosimilar has several advantages over other therapeutic antibodies currently available in the market. Firstly, being a biosimilar, it has a similar structure and mechanism of action to the original drug, making it a more cost-effective option. Additionally, its humanized structure reduces the risk of immunogenicity and improves its safety profile. Moreover, its high specificity for the HSP90 homolog makes it a targeted therapy, minimizing potential side effects.
In conclusion, Efungumab Biosimilar is a promising therapeutic antibody that specifically targets the HSP90 homolog, a protein overexpressed in many types of cancer. Its mechanism of action involves inhibiting the chaperone function of the HSP90 homolog, leading to the degradation of oncogenic proteins and inhibition of cancer cell growth. With its potential applications in various diseases and advantages as a therapeutic antibody, Efungumab Biosimilar holds great promise in the field of biopharmaceuticals.
ProteoGenix catalogue number PX-TA1127. For research use only.
Target: Efungumab Biosimilar – Anti-HSP91 homolog mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Efungumab Biosimilar – Anti-HSP91 homolog mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
